Compare · MRNA vs SRRK
MRNA vs SRRK
Side-by-side comparison of Moderna Inc. (MRNA) and Scholar Rock Holding Corporation (SRRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and SRRK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $26.76B, about 4.2x SRRK ($6.44B).
- Over the past year, MRNA is up 113.5% and SRRK is up 38.7% - MRNA leads by 74.9 points.
- MRNA has been more active in the news (9 items in the past 4 weeks vs 8 for SRRK).
- MRNA has more recent analyst coverage (25 ratings vs 19 for SRRK).
- Company
- Moderna Inc.
- Scholar Rock Holding Corporation
- Price
- $67.43+0.66%
- $53.76-1.68%
- Market cap
- $26.76B
- $6.44B
- 1M return
- +35.80%
- +20.34%
- 1Y return
- +113.52%
- +38.65%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2018
- News (4w)
- 9
- 8
- Recent ratings
- 25
- 19
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester
- Moderna Science Day Highlights Expanding Potential of mRNA Platform
- Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
Latest SRRK
- Director Burow Kristina sold $164,064 worth of shares (3,053 units at $53.74), decreasing direct ownership by 3% to 114,657 units (SEC Form 4) (tax liability)
- Director Flier Jeffrey S. sold $164,490 worth of shares (3,053 units at $53.88), decreasing direct ownership by 10% to 27,856 units (SEC Form 4) to cover withholding tax
- Director Gilman Michael sold $137,058 worth of shares (2,544 units at $53.87), decreasing direct ownership by 4% to 59,511 units (SEC Form 4) (tax withholding)
- Director Reed Joshua sold $164,067 worth of shares (3,053 units at $53.74), decreasing direct ownership by 14% to 19,518 units (SEC Form 4) to cover taxes
- Director Peng Katie sold $293,405 worth of shares (5,446 units at $53.88), decreasing direct ownership by 14% to 34,301 units (SEC Form 4) (withholding tax)
- SEC Form 144 filed by Scholar Rock Holding Corporation
- SEC Form 144 filed by Scholar Rock Holding Corporation
- Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
- Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Flier Jeffrey S. was granted 6,839 shares, increasing direct ownership by 28% to 30,909 units (SEC Form 4)